Skip to content
    Schroders Capital logo

    Schroders Capital

    London, United KingdomFounded 2021
    www.schroderscapital.com/en/global/professionalLinkedIn
    AIBiotech & Life SciencesEnterprise SoftwareFintechConsumerInfrastructure & CloudHealthcare

    Schroders Capital is the private markets investment division of Schroders plc, launched as a unified brand in 2021 to consolidate Schroders' private assets businesses. It invests across private equity, venture capital and growth, real estate, infrastructure, and private debt and credit alternatives, with $112 billion in assets under management.

    32% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $153.7M (across 53 rounds with reported amounts).

    Find people at Schroders Capital on Goldilocks AI

    Portfolio

    52

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    10

    Team

    CP

    Chelsea Popkin

    Investment Director

    JK

    Jeremy Knox

    Senior Investment Director

    JL

    Jake Legotte

    Private Equity Investment Manager

    PL

    Peter Lowe

    Head of UK Real Estate Investment

    RP

    Richard Pinto

    Private Equity Investment Manager

    CV

    Christiaan van der Kam

    Head of Secondaries Private Equity

    DR

    Dan Rhoads

    Private Equity

    DB

    David Bajada

    Co-Head of Private Equity Investments Asia

    JM

    James MacNamara

    Global Head of Value Add and Alternatives, Real Estate

    JN

    Jerome Neyroud

    Head of Infrastructure Debt Investments

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    75 investments
    CompanyRoundAmountDate
    Draig Therapeutics logoDraig TherapeuticsSeries B$65MJul 2026
    Kainova Therapeutics logoKainova TherapeuticsSeries B—Feb 2026
    TEM logoTEMSeries B$75MFeb 2026
    TEM logoTEMSeries C$75MFeb 2026
    Kinaset Therapeutics logoKinaset TherapeuticsSeries B$103MJan 2026
    KKinasetSeries B$103MJan 2026
    MMultiverse LabsSeries D$15MJan 2026
    TTem EnergySeries B$75MJan 2026
    MMultiverse Group LimitedUnknown$70MJan 2026
    Wayve logoWayveSeries D$1.2BJan 2026
    EEleven Labs, Inc.Series D—Jan 2026
    SSuno AiSeries D$400MJan 2026
    MoEngage Inc. logoMoEngage Inc.Series F$180MDec 2025
    Artios logoArtiosSeries D$115MNov 2025
    AAVantgarde Bio logoAAVantgarde BioSeries B—Nov 2025
    Vercel logoVercelGrowth—Sep 2025
    Draig Therapeutics logoDraig TherapeuticsSeries A$140MJun 2025
    Haya Therapeutics logoHaya TherapeuticsSeries A$65MMay 2025
    Neurona Therapeutics logoNeurona TherapeuticsUnknown$102MApr 2025
    Cyberhaven logoCyberhavenSeries D$100MApr 2025
    Luminance logoLuminanceSeries C—Feb 2025
    Cera Care logoCera CareGrowth$150MJan 2025
    Draig Therapeutics logoDraig TherapeuticsSeries A$140MJan 2025
    Neurona logoNeuronaSeries A$102MJan 2025
    Luminance logoLuminanceSeries C$75MJan 2025
    Page 1 of 3

    Top Co-Investors

    StepStone Group12 shared
    Lightspeed Venture Partners10 shared
    RA Capital Management10 shared
    SV Health Investors9 shared
    Sofinnova Partners9 shared
    EQT Life Sciences8 shared
    M Ventures8 shared
    Willett Advisors7 shared
    Vi Partners7 shared
    Adams Street Partners6 shared
    General Catalyst6 shared
    Andera Partners6 shared
    Omega Funds6 shared
    IP Group plc6 shared
    Avidity Partners6 shared
    Pfizer Ventures6 shared
    The Invus Group, LLC6 shared
    Bpifrance6 shared
    Bain Capital Ventures5 shared
    DST Global5 shared

    Last updated: 7 October 2026